BETHESDA, Md--At its most recent meeting, the National Cancer
Advisory Board heard a report on the Division of Cancer Treatment,
Diagnosis, and Centers and its efforts to promote third-party
payer support for clinical trials.
Mary McCabe, representing the division, said that it meets regularly
with insurers, government agencies, and trade associations to
establish and build partnerships for education on clinical trials
and to increase support for third-party coverage.
The division emphasizes to insurers that clinical trials give
good value because they have rigid review systems, provide outcome
measures, and have in place the necessary quality assurances for
In 1993, she said, the first part of a congressionally mandated
two-part study to determine third-party reimbursement policies
was completed. This study included a survey of eight insurers
and managed care organizations.
Meeting Being Arranged
Currently, Ms. McCabe said, a meeting is being arranged between
NCI Director Richard Klausner and a group of representative insurers
to discuss their interest in cancer care. The division is also
planning discussions with large corporations. Meanwhile, she said,
discussions continue with patient advocacy groups, Federal agencies,
legislators, national organizations, and other NIH institutions.